Stryker Corporation

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

BTIG Reaffirms Their Buy Rating on Stryker (SYK)

📈 BTIG analyst Ryan Zimmerman reaffirmed a Buy rating on Stryker (SYK) with a price target of $379.00.

💰 Stryker shares closed at $315.13, presenting an opportunity for upside potential below the consensus price target of $415.94.

📊 The company reported Q4 revenue of $7.17 billion and net profit of $849 million, up from $6.44 billion and $546 million respectively in the prior year.

⚠️ Corporate insider sentiment is negative due to increased selling activity over the past quarter among 53 insiders.

👩‍💼 Director Ronda Stryker recently sold 500,000 shares for approximately $181.7 million in February 2026.

📉 Q1 adjusted earnings per share came in at $2.60, missing the analyst consensus estimate of $2.98.

🎯 Management maintained its full-year 2026 adjusted EPS outlook between $14.90 and $15.10, aligning closely with the consensus of $14.96.

⚖️ Despite the negative insider activity, the overall analyst consensus for Stryker remains Strong Buy.

🏥 Canaccord Genuity also maintained a Buy rating on the stock with a price target of $400.00.

🔍 Zimmerman covers the Healthcare sector including peers like GE Healthcare Technologies and Alcon.

📉 His historical performance shows an average return of -0.6% and a 39.60% success rate over his career.

Full Analysis
BTIG analyst Ryan Zimmerman reaffirmed a Buy rating on Stryker (SYK), setting a price target of $379.00, while the stock closed at $315.13. TipRanks notes that Zimmerman covers the Healthcare sector with an average return of -0.6% and a 39.60% success rate. The broader analyst consensus for Stryker remains Strong Buy, with a price target consensus of $415.94, indicating potential upside of approximately 32%. Additionally, Canaccord Genuity also maintained its Buy rating on the stock with a $400.00 price target in their latest report. Stryker reported strong financial results for the quarter ending December 31, delivering quarterly revenue of $7.17 billion and a net profit of $849 million, compared to $6.44 billion in revenue and $546 million in net profit from the prior year. The company also provided guidance for the current fiscal year, maintaining an adjusted EPS outlook between $14.90 and $15.10, which aligns closely with the consensus estimate of $14.96. Stryker reported a Q1 adjusted EPS of $2.60 against a consensus of $2.98. Despite the bullish analyst sentiment and strong earnings growth, corporate insider activity currently shows negative sentiment on the stock due to recent selling by 53 insiders. Specifically, in February 2026, Director Ronda Stryker sold 500,000 shares for a total value of $181.7 million. This increase in insider selling contrasts with the positive external analyst ratings and recent financial performance.